News FDA approves Roche potential haemophilia blockbuster Blood cancer drug Gazyva also gets new US use
News NICE backs funding for Pfizer, Novartis breast cancer drugs Pfizer had been giving drug free to NHS before decision
News Reimbursement remains biggest barrier to precision drugs Reimbursement more of a barrier than regulation
News Roche’s MS drug Ocrevus nears European market Roche's new multiple sclerosis drug Ocrevus (ocrelizumab) gained FDA approval in March, and since then has achieved remarkable revenues of half a billion dollars in the year to date.<
News NICE to play key role in UK drug fast-track scheme Former GSK CEO Sir Andrew Witty will oversee proceedings.
News NHS England chief hails ‘precedent setting’ outcomes deal wi... NHS England unveiled two new bespoke pricing deals with pharma companies yesterday, underlining its growing direct engagement with the industry.
News Gilead strikes again, penning $5bn deal to buy Tubulis Gilead has signed its third acquisition deal since the start of the year, agreeing to buy ADC specialist Tubulis for $3.15bn upfront.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
